1. EMA, EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity: some valsartan medicines being recalled across the EU. (5 July 2018) 〈https://www.ema.europa.eu/en/news/ema -reviewing -medicines -containing -valsartan - zhejiang-huahai-following-detection-impurity-some〉.
2. Control of Nitrosamine Impurities in Human Drugs; Guidance for Industry; Availability. U.S. Food & Drug Administration Documents/FIND. 〈https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamineimpurities-human-drugs〉.
3. The hazard of N-nitrosodimethylamine (NDMA) formation during water disinfection with strong oxidants;Andrzejewski;Desalination,2005
4. Medicines and healthcare products regulatory agency, Interim guidance on a strategy for genotoxicity testing and mutagenic hazard assessment of impurities in chemical substances (April 2012). 〈https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/315779/impurities.pdf〉.
5. European Medicines Agency, EMA to provide guidance on avoiding nitrosamines in human medicines (2019). 〈https://www.ema.europa.eu/en/documents/press-release/ema-provide-guidance-avoiding-nitrosamines-human-medicines_en.pdf〉.